129 related articles for article (PubMed ID: 8938138)
1. Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.
Wang Z; Lee KB; Reed E; Sinha BK
Int J Cancer; 1996 Nov; 68(5):583-7. PubMed ID: 8938138
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.
Wang Z; Benchekroun MN; Sinha BK
Anticancer Res; 1994; 14(5A):1723-6. PubMed ID: 7847805
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Wang Z; Sinha BK
Mol Pharmacol; 1996 Feb; 49(2):269-75. PubMed ID: 8632759
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3).
Monti E; Mimnaugh EG; Sinha BK
Biochem Pharmacol; 1993 May; 45(10):2099-107. PubMed ID: 8512591
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha.
Benchekroun MN; Parker R; Reed E; Sinha BK
Biochem Biophys Res Commun; 1993 Aug; 195(1):294-300. PubMed ID: 8363610
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
8. Effects of interleukin-1 alpha on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: implications in the mechanism of sensitization of cis-diamminedichloroplatinum(II).
Benchekroun MN; Parker R; Dabholkar M; Reed E; Sinha BK
Mol Pharmacol; 1995 Jun; 47(6):1255-60. PubMed ID: 7603468
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Usui N; Matsushima K; Pilaro AM; Longo DL; Wiltrout RH
Biotherapy; 1996; 9(4):199-208. PubMed ID: 9012539
[TBL] [Abstract][Full Text] [Related]
10. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models.
Zajchowski DA; Biroc SL; Liu HL; Chesney SK; Hoffmann J; Bauman J; Kirkland T; Subramanyam B; Shen J; Ho E; Tseng JL; Dinter H
Int J Cancer; 2005 May; 114(6):1002-9. PubMed ID: 15645422
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3).
Kilian PL; Kaffka KL; Biondi DA; Lipman JM; Benjamin WR; Feldman D; Campen CA
Cancer Res; 1991 Apr; 51(7):1823-8. PubMed ID: 1825935
[TBL] [Abstract][Full Text] [Related]
16. The plant extract of Pao pereira potentiates carboplatin effects against ovarian cancer.
Yu J; Chen Q
Pharm Biol; 2014 Jan; 52(1):36-43. PubMed ID: 24033267
[TBL] [Abstract][Full Text] [Related]
17. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
[TBL] [Abstract][Full Text] [Related]
20. [Synergistic effects of tumor necrosis factor interferon-gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro].
Li J; Hui N; Zhu L
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):429-31. PubMed ID: 8697994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
